3 min readLenvatinib plus pembrolizumab improved survival outcomes in advanced endometrial cancerUterine cancer is the second most prevalent Gynecological cancer in the world and it has high incidence rates in developed countries.
3 min readDostarlimab receives approval as a revolutionary treatment in endometrial cancerEndometrial cancer, the most prevalent uterine cancer subtype, is the fourth most common cancer among women worldwide.
